Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.8 USD | +2.66% | -0.65% | -29.80% |
Financials (USD)
Sales 2024 * | 611M | Sales 2025 * | 705M | Capitalization | 2.31B |
---|---|---|---|---|---|
Net income 2024 * | 117M | Net income 2025 * | 183M | EV / Sales 2024 * | 2.92 x |
Net cash position 2024 * | 521M | Net cash position 2025 * | 621M | EV / Sales 2025 * | 2.39 x |
P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
14.1
x | Employees | 352 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.25% |
Latest transcript on Corcept Therapeutics Incorporated
1 day | +2.66% | ||
1 week | +2.24% | ||
Current month | -9.49% | ||
1 month | -9.95% | ||
3 months | +2.10% | ||
6 months | -16.36% | ||
Current year | -29.80% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 98-05-12 |
Atabak Mokari
DFI | Director of Finance/CFO | 47 | 21-02-28 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 46 | 12-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 98-05-12 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-03-11 |
George Baker
BRD | Director/Board Member | 81 | 98-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.71% | 29 M€ | -4.33% | ||
0.30% | 45 M€ | +0.20% | ||
0.27% | 27 M€ | -5.03% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 22.8 | +2.66% | 820,436 |
24-04-25 | 22.21 | -1.20% | 1,176,227 |
24-04-24 | 22.48 | -2.26% | 1,087,749 |
24-04-23 | 23 | +3.14% | 1,885,132 |
24-04-22 | 22.3 | -2.83% | 3,897,981 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.80% | 2.31B | |
+25.83% | 653B | |
+27.00% | 556B | |
-6.76% | 354B | |
+20.34% | 331B | |
+3.00% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.26% | 144B |
- Stock Market
- Equities
- CORT Stock